Planned Weekly Dose

On average, during the first 8 weeks of the phase 3 Global ARCC study…

More than 90% of the TORISEL planned weekly dose was delivered to patients1

Results from a phase 3, multicenter, randomized, open-label study in previously untreated patients with advanced RCC who had =3 of 6 preselected prognostic risk factors. Patients received TORISEL (n=209, 25 mg IV once weekly) or IFNa (n=207, maximum 18 MU SubC 3 times weekly).
  • On average, TORISEL patients received 92% of the planned weekly dose (mean, 23 mg out of a planned 25 mg) during the first 8 weeks of the study1
  • On average, IFNa patients received 56% of the planned weekly dose (mean, 30 MU out of a planned 54 MU) during the first 8 weeks of the study1

REFERENCE
  1. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.